ArticleScientific reports2025
ATF6 and pS6K as prognostic biomarkers in newly diagnosed diffuse large B-cell lymphoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the clinical and prognostic significance of activating transcription factor 6 (ATF6) and phosphorylated S6 kinase (pS6K) expression in newly diagnosed diffuse large B-cell lymphoma (DLBCL). We conducted a retrospective analysis of 107 DLBCL patients treated with the R-CHOP regimen at the Department of Hematology, Fourth Hospital of Hebei Medical University, between January 2019 and December 2022. Immunohistochemical staining was performed to evaluate ATF6 and pS6K expression levels in tumor tissues, followed by correlation analyses with clinical features and survival outcomes. Elevated ATF6 and pS6K expression levels were significantly correlated with advanced Ann Arbor stage (III-IV), presence of B symptoms, high International Prognostic Index (IPI) scores (≥ 2), extranodal involvement (> 1 site), peripheral blood lymphopenia (< 1.1 × 10
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.